HC Wainwright Has Bearish Estimate for AKBA FY2026 Earnings

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Stock analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will earn ($0.18) per share for the year, down from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at ($0.10) EPS and FY2030 earnings at ($0.05) EPS.

A number of other equities research analysts have also issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $4.00 price target on shares of Akebia Therapeutics in a report on Tuesday, September 15th. Westpark Capital began coverage on shares of Akebia Therapeutics in a research report on Tuesday, September 8th. They issued a “buy” rating and a $4.50 price objective on the stock. Wall Street Zen downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Leerink Partners lowered shares of Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 target price for the company. in a report on Friday, August 7th. Finally, Weiss Ratings cut Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Akebia Therapeutics presently has an average rating of “Hold” and a consensus price target of $3.90.

Akebia Therapeutics Price Performance

NASDAQ:AKBA opened at $0.53 on Tuesday. The company has a fifty day moving average of $0.81 and a 200 day moving average of $1.12. Akebia Therapeutics has a 52 week low of $0.36 and a 52 week high of $1.89. The company has a current ratio of 1.43, a quick ratio of 1.35 and a debt-to-equity ratio of 0.99.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%. The business had revenue of $36.90 million for the quarter, compared to analysts’ expectations of $46.94 million.

Institutional Trading of Akebia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtus Advisers LLC increased its stake in shares of Akebia Therapeutics by 16.1% in the 3rd quarter. Virtus Advisers LLC now owns 366,672 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 50,935 shares in the last quarter. Alps Advisors Inc. boosted its stake in Akebia Therapeutics by 33.7% during the third quarter. Alps Advisors Inc. now owns 364,094 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 91,832 shares in the last quarter. State of Wyoming boosted its stake in Akebia Therapeutics by 1,090.7% during the third quarter. State of Wyoming now owns 192,008 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 175,883 shares in the last quarter. PFG Private Wealth Management LLC purchased a new stake in Akebia Therapeutics in the third quarter worth about $34,000. Finally, Headlands Technologies LLC grew its holdings in Akebia Therapeutics by 60.3% in the second quarter. Headlands Technologies LLC now owns 77,992 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 29,334 shares during the period. 33.92% of the stock is currently owned by hedge funds and other institutional investors.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation.